BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Special Report

All Special Reports
Datamonitor Healthcare Ulcerative Colitis KOL Interviews

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in
August 18, 2017
Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC. The specific drugs discussed include alicaforsen, Entyvio / vedolizumab [TKPYY], etrolizumab [RHHBF], filgotinib [GILD], Humira / adalimumab [ABBV], Inflectra / infliximab biosimilar, LT-02 [NSRGY], Ozanimod [CELG], Remicade / infliximab [JNJ], Simponi (SQ) / golimumab [JNJ], Stelara / ustekinumab [JNJ] and Xeljanz / tofacitinib [PFE]. The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Ulcerative Colitis (UC)